Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.
暂无分享,去创建一个
Paolo Prandoni | Antonio Girolami | Paolo Simioni | M. Prins | P. Prandoni | E. Bernardi | P. Simioni | A. Girolami | B. Girolami | A. Piccioli | Martin H Prins | Andrea Piccioli | A. Lensing | A. Marchiori | Enrico Bernardi | F. Noventa | Franco Noventa | Anthonie W A Lensing | Antonio Marchiori | Bruno Girolami | Paola Sabbion | P. Sabbion | Paola Sabbion
[1] Vittorio Pengo,et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) , 1996, The Lancet.
[2] H. Büller,et al. Diagnosis of recurrent deep vein thrombosis. , 1995, Haemostasis.
[3] Edward Pan,et al. Glioblastoma Multiforme and Anaplastic Astrocytoma , 2003 .
[4] W. Henderson,et al. Bleeding complications from warfarin anticoagulation in patients with malignancy. , 1987, Journal of medicine.
[5] Jeffrey S. Ginsberg,et al. Management of venous thromboembolism. , 1996, The New England journal of medicine.
[6] G. Hughes,et al. The management of thrombosis in the antiphospholipid-antibody syndrome. , 1995, The New England journal of medicine.
[7] Paolo Prandoni,et al. The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.
[8] J. Levin,et al. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. , 1977 .
[9] N. Callander,et al. Trousseau's syndrome. , 1993, The Western journal of medicine.
[10] H. Büller,et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis , 1992, The Lancet.
[11] J. Hirsh,et al. Diagnosis of pulmonary embolism. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[12] A. Alavi,et al. The clinical course of pulmonary embolism. , 1992, The New England journal of medicine.
[13] M. Prins,et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutationRisk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis , 2000 .
[14] F. Barral,et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. , 1998, The New England journal of medicine.
[15] F. Rickles,et al. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. , 1983, Blood.
[16] J. Levin,et al. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. , 1977, Medicine.
[17] G. Raskob,et al. A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. , 1984, JAMA.
[18] J. Vandenbroucke,et al. Bleeding Complications in Oral Anticoagulant Therapy , 1993 .
[19] J. Hirsh,et al. A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy , 2000, Thrombosis and Haemostasis.
[20] S. Green,et al. Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications , 1985, Cancer.
[21] M. Baccarani,et al. Staging and prognosis in chronic myelogenous leukemia. , 1988, Seminars in hematology.
[22] J. Vandenbroucke,et al. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. , 1993, Archives of internal medicine.
[23] B. Gersh,et al. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. , 1995, Mayo Clinic proceedings.
[24] S. Salmon,et al. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.
[25] M Gent,et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M H Prins,et al. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. , 2000, Archives of internal medicine.
[27] M. Prins,et al. Deep-vein thrombosis , 1999, The Lancet.
[28] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[29] M. Prins,et al. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. , 1997, The New England journal of medicine.
[30] Mark J. Thomas,et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.
[31] Marcel Levi,et al. Disseminated Intravascular Coagulation , 1999 .
[32] D M Wallace,et al. The Efficacy and Safety of Oral Anticoagulation in Patients with Cancer , 1995, Thrombosis and Haemostasis.
[33] M. Prins,et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. , 1992, The New England journal of medicine.
[34] P. Prandoni,et al. Noninvasive objective tests for the diagnosis of clinically suspected deep-vein thrombosis. , 1995, Haemostasis.
[35] P. Bossuyt,et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. , 1996, The New England journal of medicine.